2018 2018-12-11 Camurus Capital Markets and R&D Day 11 December 2018 2018-11-28 Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence 2018-11-28 Program for Camurus Capital Markets and R&D Day 11 December 2018 2018-11-22 Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence 2018-10-25 Interim Report January-September 2018 2018-10-16 Camurus’ Nomination Committee appointed for the Annual General Meeting 2019 2018-10-10 Camurus to present at Jefferies 2018 London Healthcare Conference 2018-10-09 Save the date: Camurus Capital Markets and R&D Day 11 December 2018 2018-09-21 CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence 2018-09-18 Camurus announces positive topline Phase 3 results for CAM2038 in opioid experienced patients with chronic low-back pain 2018-07-17 Interim Report January-June 2018 2018-07-16 Camurus announces PDUFA date for CAM2038 for the treatment of opioid use disorder 2018-06-29 Change in the number of shares and votes in Camurus AB 2018-06-29 Camurus has completed a directed share issue of 1.1 million shares, raising proceeds of approximately SEK 102 million 2018-06-28 Camurus updates its investor relations website 2018-06-28 Camurus intends to launch a directed share issue of approx. MSEK 100 2018-06-12 Camurus and Medison enter into commercialization agreement for CAM2038 in Israel 2018-05-31 Camurus announces positive topline results from Phase 1 study of long-acting treprostinil for the treatment of pulmonary arterial hypertension 2018-05-28 Camurus announces NDA resubmission of weekly and monthly buprenorphine depots to FDA 2018-05-25 Camurus to present at the Jefferies 2018 Global Healthcare Conference 2018-05-14 JAMA Internal Medicine publishes positive Phase 3 pivotal study results for Camurus’ long-acting buprenorphine depots for opioid use disorder 2018-05-03 Resolutions at the annual general meeting 2018 in Camurus 2018-05-03 Interim Report January-March 2018 2018-05-03 Camurus regains worldwide development and commercialization rights to CAM2029 and related product candidates 2018-03-23 Notice of annual general meeting 2018 in Camurus AB (publ) 2018-03-22 Camurus Annual Report for 2017 2018-03-08 Camurus to present at the Cowen and Company Annual Healthcare Conference 2018 2018-02-15 Full year report 2017 2018-01-21 FDA issues complete response letter for CAM2038 for opioid use disorder 2017 2017-12-21 First cohort dosed in Phase 1 clinical study of sustained release treprostinil injection for treatment of PAH 2017-11-07 Camurus to present at Jefferies 2017 London Healthcare Conference 2017-11-01 Camurus announces that FDA advisory committee recommends approval of CAM2038 for treatment of opioid use disorder 2017-10-30 Camurus announces that FDA has posted briefing material for CAM2038 Advisory Committee meeting 2017-10-26 Interim Report January-September 2017 2017-10-20 Nomination Committee appointed in respect of AGM 2018 in Camurus 2017-09-29 Camurus announces European Medicines Agency validation of CAM2038 Marketing Authorization Application for treatment of opioid dependence 2017-09-18 Camurus Announces that FDA Grants Priority Review of NDA for Weekly and Monthly CAM2038 Buprenorphine Depots for Treatment of Opioid Use Disorder 2017-07-20 Camurus and Braeburn Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder 2017-07-13 Interim report January-June 2017 2017-07-12 Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results for Long-acting Buprenorphine in Opioid Dependent Patients with Chronic Pain 2017-06-27 Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity 2017-06-22 Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder 2017-06-15 Camurus and Braeburn Pharmaceuticals Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine 2017-05-03 Resolutions at the annual general meeting 2017 in Camurus 2017-05-03 Interim Report January-March 2017 2017-05-02 Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038 2017-03-31 Camurus appoints VP Corporate Development & General Counsel 2017-03-30 Camurus Annual Report for 2016 released 2017-03-30 Notice of annual general meeting 2017 in Camurus AB (publ) 2017-03-09 Ethypharm and Camurus sign agreement for distribution of episil® in France 2017-02-16 Full year report 2016 2017-02-02 Camurus to present at the Cowen and Company Annual Healthcare Conference 2017 2017-01-09 Camurus to present at the J.P. Morgan Annual Healthcare Conference 2017 2016 2016-12-14 Camurus Capital Markets and R&D Day 2016 2016-11-25 Program for Camurus’ Capital Markets and R&D Day 14 December 2016 2016-11-14 Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine for Treatment of Opioid Addiction 2016-11-11 Camurus to provide an update on the progress of its research and development programs at the Jefferies 2016 Healthcare Conference 2016-11-08 Interim report January-September 2016 2016-11-01 Camurus to host a Capital Markets Day 14 December 2016 2016-10-28 Nomination Committee appointed in respect of AGM 2017 in Camurus 2016-10-24 Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to include New Combination Product for Pain and Nausea 2016-10-21 Braeburn Pharmaceuticals and Camurus announce the presentation of new data from clinical studies of long-acting buprenorphine 2016-09-30 Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for treatment of Chronic Low Back Pain 2016-07-14 Interim report January-June 2016 2016-07-12 Camurus announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors 2016-06-21 Camurus announces results from a Phase 2 trial of CAM2032 in patients with prostate cancer 2016-06-20 Richard Jameson assumes position as Camurus’ Chief Commercial Officer 2016-05-17 Camurus Interim Report January-March 2016 2016-05-11 Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder 2016-05-03 Resolutions at the Annual General Meeting 2016 in Camurus 2016-04-21 Distribution agreement signed with R-PHARM US for episil® 2016-04-05 Braeburn Pharmaceuticals and Camurus announce Enrollment goals reached in two pivotal Phase 3 Trials of CAM2038 for treatment of opioid dependence 2016-03-30 Notice of annual general meeting 2016 and proposal for new incentive program in Camurus AB (publ) 2016-03-30 Camurus Annual Report for 2015 released 2016-02-22 Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain 2016-02-17 Full year report January-December 2015 2016-02-04 Nomination Committee appointed in respect of AGM 2016 in Camurus 2016-01-05 Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide 2015 2015-12-30 Braeburn Pharmaceuticals and Camurus enroll first patient in a phase 3 efficacy trial of long-acting treatment for opioid dependence 2015-12-30 Change in the number of shares and votes in Camurus 2015-12-15 Braeburn Pharmaceuticals and Camurus announce start of Phase 3 trial of long-acting buprenorphine treatments for opioid dependence 2015-12-14 Camurus appoints Chief Commercial Officer 2015-12-10 Exercise of the over-allotment option in the initial public offering of Camurus 2015-12-03 Final price in Camurus’s initial public offering set at SEK 57 per share – trading on Nasdaq Stockholm commences today 2015-11-19 Camurus announces initial public offering on Nasdaq Stockholm 2015-11-18 Camurus announces initial public offering on Nasdaq Stockholm 2015-11-04 FDA grants Fast Track designation for development of CAM2038, long-acting buprenorphine injections to treat opioid addiction 2015-10-22 Camurus AB Interim Report, January - September 2015 2015-03-30 Solasia acquires exclusive license and distribution rights from Camurus for episil® oral liquid in Japan and China 2014
2014-11-20 Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain
more information Accept
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.